March 2, 2019
Many of you know, Canary Foundation believes in collaborations, including partnerships we have fostered on a global level. So this is to announce that registration is open for this second annual conference, a next generation outgrowth of our science symposium, led by our partners. The location is Stanford University.
Looking back to 2005, Canary Foundation held the first symposium fully dedicated to cancer early detection. Long before the term became common. What did we want to achieve? Our goal was to catalyze the field and bring early detection to the foreground. Early detection saves lives! By 2017, we were attracting 200 scientists and experts. Together, they ask important questions, have dynamic conversations and form innovative ideas. Additionally, presenters offer information on promising projects.
In 2018, our international partners took on leading the conference. The Canary Center at Stanford, Cancer Research United Kingdom, and the Knight Cancer Institute at Oregon Health & Science University together held their first in 2017. They also agreed to rotate locations. So this year, in 2019, the Canary Center will host the conference at Stanford University.
The Canary Center at Stanford represents a partnership between Canary Foundation and Stanford University. You may know, we celebrated the opening in 2009 as the first research center in the world, entirely dedicated to cancer early detection. Cancer Research United Kingdom is the largest independent funder of cancer research globally. The Knight Cancer Institute at Oregon Health & Science University, is a leader in precision cancer medicine. To visit the conference site and register: Early Detection of Cancer Conference
February 3, 2019
What if we could view changes in the body earlier than early to warn of possible disease? That is the aim of Project Baseline, to map human health. The New York Times published “Project Baseline Aims to Ward Off Illness Before We Get Sick” by Anahad O’Connor (Oct 2018). The study is recruiting 10,000 adults. And each will be examined and followed for at least four years. So the goal is to discover the earliest warning signs of cancer, heart disease and other killers. Participants, the first of whom was enrolled in 2017, are called Baseline Explorers.
Project Baseline is the result of conversations in 2013, led by Google X’s Andrew Conrad. He consulted with Dr. Sam Gambhir, MD, chair of Radiology at Stanford University and director of the Canary Center for Cancer Early Detection. And also with Robert M. Califf, MD, professor of Cardiology in the School of Medicine, Duke University.
Conrad (now CEO of Verily, a spin out of Google X) was interested in exploring with these two notable healthcare thought leaders, one in cancer and the other in cardiology, about how to create what has become a landmark study. Both had deep experience in working with large patient cohorts and focus on early detection of disease. The project has formed teams across the country.
Seeking to create a baseline of health
Traditional trials focus on those who have a disease. So Project Baseline, as the name implies, mainly enrolls healthy individuals gathering enormous amounts of information. Baseline equips enrollees with wearable technology from Verily that tracks sleep patterns, heart rhythms and physical activity. The team is developing tools and technologies to collect, organize, analyze and curate the data.
And investigators are determining the best ways to share data with participants that is helpful to them. They are looking at how they can engage with their medical professionals.
Canary Foundation and the Canary Center at Stanford for Cancer Early Detection
Dr. Gambhir has served as Canary Foundation’s scientific director for more than a decade. He led the development of the Canary Center at Stanford for Cancer Early Detection. The Canary Center is a partnership forged in 2008 between Stanford University and Canary Foundation under the leadership of Don Listwin, based on the foundation’s mission. And interesting to know, Canary Center is the first program Stanford has focused entirely on cancer early detection.
American Cancer Society Report January 2019 is hopeful. Yet it motivates us to work harder at finding better tests
January 16, 2019
The new American Cancer Society report shows us that cancer deaths have dropped by 27% since their peak in 1991. The decrease is attributed to early detection, better treatments and a reduction in smoking rates. The ACS report also points to a socio-economic disparity in the numbers, based on broad county and area reports collected by Surveillance, Epidemiology, and End Results (SEER – a National Cancer Institute source of epidemiologic information on the incidence and survival rates of cancer in the United States, where access to education and healthcare remains a problem. Additionally, lower incidence has been slower in cancers such as lung and prostate. Also, rates of new cases rose for pancreatic and other cancers. While the overall decline in rates is great news, we must keep up the momentum to create early detection tests to save lives as cancer remains the second cause of death in the United States (22% in 2016), and a major health issue worldwide.
The report states that in 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. From the report: “…the Lifetime probability of being diagnosed with invasive cancer is 39.3 % for men and 37.7% for women. Prostate, lung and colorectal cancers (CRCs) account for 42% of all cases in men, with prostate cancer alone accounting for nearly 1 in 5 new diagnoses. For women, the 3 most common cancers are breast, lung, and colorectum, which collectively represent one-half of all new diagnoses; breast cancer alone accounts for 30% of all new cancer diagnoses in women. The reasons for the excess overall risk in men are not fully understood, but partly reflect differences in environmental exposures, endogenous hormones, and probably complex interactions between these influences.”
Canary Foundation has been on the forefront of stimulating the field of cancer early detection globally by demonstrating cancer early detection tests as well as hosting scientific symposiums, mentoring researchers choosing the early detection path, and forging important national and international partnerships. To address access problems, Canary’s investments have focused, when possible, on cost-effective tests as a path to bridging the socio-economic disparities. Examples can be found in are our funded studies in enhance ultrasound using microbubbles, where ultrasound is found in doctor’s offices worldwide, representing an imaging modality in development useful for multiple cancers that is low-cost, non- invasive and with the additional benefit of not using radiation.
Canary Founder Don Listwin was awarded the prestigious Dean’s Medal for his contribution to Stanford Medicine
December 24, 2018
Listwin was one of only three recipients selected in 2018 to receive the highest honor bestowed by the Stanford University School of Medicine, the Dean’s Medal, which is presented to individuals who have significantly advanced the mission of Stanford Medicine.
Living through his mother’s death from ovarian cancer left an indelible mark on Listwin and inspired him to work toward progress in early cancer detection. Listwin’s role in helping to create today’s global internet infrastructure through multibillion-dollar technology investing and management, including a decade at Cisco Systems, enabled him to step back from his operating roles to build the Canary Foundation.
Today, 15 years later, the Canary Foundation has grown from a startup nonprofit to a leader in the development of early cancer detection programs, including the Canary Center at Stanford and many others in the United States and abroad. The Canary Foundation is the only nonprofit exclusively dedicated to research in the field of early detection of cancer. The Dean’s Medal honors Listwin for his service in the scientific and philanthropic communities that have advanced precision health.
“My thanks to Dean Minor and the entire School of Medicine organization,” Listwin said. “Over the past decade, a theme of partnership has emerged in my pursuits in the medical field, and none has been stronger than at Stanford. Whether working with Dr. Sam Gambhir to build the first comprehensive early cancer detection center or launching a modest vision clinic in Belize with Dr. Caroline Fisher, there has always been support from the School of Medicine. My current pursuit in the field of stroke also found it roots at Stanford. It is a privilege to be able to engage in a spectrum of work in the field of medicine with the best in the world to help solve these critical problems.”
The other recipients are Carla Shatz, PhD, the Sapp Family Provostial Professor, the David Starr Jordan Director of Stanford Bio-X and a professor of biology and of neurobiology; and Ron Johnson, founder and CEO of Enjoy, a company that hand-delivers technology products and helps customers set them up.
Christina Curtis, PhD, assistant professor of medicine and genetics and an associate member of the Canary Center at Stanford for Cancer Early Detection, was awarded the Pioneer Award in October from the National Institutes of Health. The award provides up to $3.5 million, dispensed over five years, to investigators at all career levels to pursue new research directions and develop groundbreaking, high-impact approaches to a broad area of biomedical or behavioral science.
Curtis plans to use her award to study how human tumors develop and to predict their progression. Her research focuses on understanding cancer systems biology, or the complex way in which many aspects of biology interact in healthy and diseased states. Akin to weather forecasting, the goal is to ultimately allow clinicians to anticipate how a tumor will behave over time, as well as to steer its course and tailor treatment options.
“Characterizing how a patient’s tumor changes over time, adapts to therapy and sometimes spreads to other tissues is challenging since this process often cannot be directly measured,” Curtis said. “Yet, learning cancer’s evolutionary rulebook will give us clues about a patient’s prognosis and is a necessary step toward the development of predictive models.”
To overcome these challenges, Curtis has developed powerful computational and statistical techniques to infer an evolutionary history of tumors by analyzing the patterns of mutations present in their genomes and comparing these with virtual tumors simulated under different scenarios. She is also working to measure tumor adaptation during development and tumor progression in real time by leveraging new methods to trace cell lineages.
August 6, 2018
Today we want to take the time to introduce you to the Canary Center’s Canary CREST internship program. The Canary CREST program pairs outstanding undergraduate students with a faculty member at the Canary Center at Stanford who then goes on to mentor them over the course of the summer. Interns work on their own personal research project with the guidance of their mentor and then present their work at the end of a summer in a poster competition held at the Canary Center at Stanford for Cancer Early Detection.
Over 200 undergraduates applied to the program, of which 27 outstanding applicants were accepted. Students come from universities located all over the country, with schools such as Yale, Stanford, Rice and an assortment of UC schools represented. This year’s class of interns are evenly divided between rising sophomores, juniors and seniors.
In addition to conducting research, the interns get the opportunity to participate in weekly classroom sessions where they learn about current research in the field of cancer early detection. They also get to participate in workshops where they hone their communication skills, are taught how to critically evaluate research, and learn about research ethics. Interns also have the opportunity to attend seminars on the Stanford campus where they get to hear from industry professionals who work for a range of companies from startups to large corporations. Interns are also given the chance to visit companies such as Verily, Google’s life sciences division.
July 30, 2018
Canary Foundation has helped launch a new website devoted to PASS (Prostate Active Surveillance Study), our research study for men who have chosen active surveillance as a management plan for their prostate cancer.
The website includes the PASS Risk Calculator, a new tool designed to estimate the likelihood that a participant’s prostate cancer will become more aggressive and require treatment.
July 11, 2018
In an effort to further the understanding of early-stage ovarian cancer and find potential ways to detect and treat it, Canary is collaborating with the BRCA Foundation on a new ovarian cancer initiative.
This initiative is being lead by Ronny Drapkin, MD, PhD, Director of the Penn Ovarian Research Center and Director of Gynecological Cancer Research at the Basser Center for BRCA at the University of Pennsylvania, and Chuck Drescher, MD, a gynecological oncologist and research scientist at the Fred Hutchinson Cancer Research Center and Director of Gynecological Research at the Swedish Medical Center in Seattle.
While there have been advances in the treatment of ovarian cancer, the same can’t be said for the development of accurate methods for detecting ovarian cancer early. As a result, most cases are diagnosed once the disease has spread beyond the ovaries to other organs.
“The most common clinical tools for diagnosing ovarian cancer, CA-125 and TV sonography, are based on technologies that are more than 25 years old,” Drescher says. “We must do better.”
Fortunately, recent scientific developments are reorienting research toward early detection by shedding light not only on how ovarian cancer forms in the body, but where it forms. It is now known, for example, that a substantial number of cases traditionally referred to as ovarian cancer don’t originate in the ovaries at all. They begin in the fallopian tubes, the structure immediately adjacent to the ovary.
“There’s been tremendous progress in our understanding of ovarian cancer in the last 5 to 10 years, and it is that progress that is serving as the basis for this new Canary initiative,” Drapkin says.
Watch the video below to learn more about these new developments in ovarian cancer.
About the initiative
April 12, 2018
Canary Foundation’s new partnership with the University of Calgary in Canada took shape recently with the announcement of four early cancer detection seed grants.
The seed grants are funded by Canary Foundation and the Charbonneau Cancer Institute at the University of Calgary. Recipients of the grants come from across the University of Calgary in the Cumming School of Medicine, Schulich School of Engineering and Faculty of Science.
The work of the recipients will focus on early detection of bladder, breast, colorectal and prostate cancer.
February 15, 2018
Juergen Willmann, MD, a professor of radiology at Stanford and a member of the Canary Foundation pancreatic team, died Jan. 8 in a car accident in Palo Alto.
Willmann was known for developing an imaging tool called targeted contrast microbubbles that, in combination with ultrasound, could be used to detect early tumors and target the delivery of drugs. Over the course of a decade, his lab at Stanford advanced the microbubble work from testing in animals all the way to the first clinical imaging trials in humans.
Here, some of Willmann’s closest colleagues share their feelings about his work, passion and the impact he had on the field of cancer early detection.
|« Older Entries|